Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
STIL
REST API REST API
Homo sapiens
STIL is differentially expressed in 251 experiments: 100 organism parts: bone marrow, lung, ... (98 more);, 210 disease states: normal, colon carcinoma, ... (208 more);, 88 cell types 317 cell lines 24 compound treatments and 72 other conditions.
Synonyms MCPH7, SIL
Orthologs STIL (Bos taurus)   Stil (Mus musculus)   stil (Danio rerio)   STIL (Gallus gallus)   ENSCING00000013128 (Ciona intestinalis)   Stil (Rattus norvegicus)   stil (Xenopus laevis)   STIL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cytoplasm, cell proliferation, negative regulation of apoptosis, smoothened signaling pathway, multicellular organism growth, centrosome, multicellular organismal development, embryonic axis specification, determination of left/right symmetry, neural tube closure, in utero embryonic development, forebrain development, notochord development, floor plate development, neural tube development, heart looping
UniProt Accession Q15468, Q5T0C7, Q5T0C6, Q5T0C9, Q5T0C8, Q5T0D4, Q5T0D0, E9PSF2
Gene-Disease Assocation MICROCEPHALY 7, PRIMARY, AUTOSOMAL RECESSIVE; MCPH7
Search EB-eye ENSG00000123473
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (31 experiments)

Factor Value U/D Experiments
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
BT474
1
2
E-MEXP-440, E-MTAB-62, E-MTAB-37
HCC2157
1
E-MTAB-37
BeWo
1
E-MTAB-37
311 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (40 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
memory B cell
2
E-MEXP-2360, E-TABM-702
peripheral blood mononuclear cell
1
E-GEOD-3026
82 more value(s).


Disease state

studied in E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (51 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
prostate carcinoma
2
E-GEOD-3868, E-MTAB-62
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
breast cancer, inflammatory
1
E-MTAB-62
204 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5099, E-GEOD-5339, E-GEOD-6431, ... (16 experiments)

Factor Value U/D Experiments
none
3
4
E-MEXP-1601, E-GEOD-412, E-TABM-782, E-GEOD-6431, E-GEOD-995, ... (7 experiments)
M-CSF
1
E-GEOD-5099
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
unknown
1
E-GEOD-7307
phoshate buffered saline
1
E-GEOD-3720
Cxcl12
1
E-GEOD-7307
18 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
1
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-20499, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-2292, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-20504, E-MEXP-1446, E-GEOD-19018, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-16363, E-GEOD-430, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363, E-GEOD-21521

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, ... (7 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.249 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM